{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"32.6","value":"27"},{"comment":"The median PFS for group 2 has not been attained","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"PFS was defined as the time from registration to progression or death due to any cause. The median PFS with 95%CI was estimated using the Kaplan Meier method.\\> Progression was defined as any one or more of the following:\\> An increase of 25% from lowest confirmed response in:\\>\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\\>\n* Urine M-component (absolute increase \\>= 200mg/24hour\\>\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl\\>\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG000","title":"LCD (Cyclophosphamide 300 mg/m^2)"},{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG001","title":"LCD (Cyclophosphamide 300 mg)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}